PinnyPeptide

AOD-9604 vs Survodutide

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

AOD-9604

Weight Management

Fat-metabolizing fragment of human growth hormone without growth-promoting effects.

Peptide B

Survodutide

Weight Management

Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials.

Typical vial

5 mg

Typical dose

250-500 mcg

Half-life

~30-60 minutes

FDA status

Not FDA approved as a drug. Granted GRAS status as a food ad…

Typical vial

10 mg

Typical dose

300-6000 mcg

Half-life

~80-90 hours (once-weekly dosing)

FDA status

Not FDA approved. Investigational compound in phase 3 clinic…

AOD-9604 effects

  • Stimulates lipolysis (fat breakdown) in adipose tissue
  • Inhibits lipogenesis (new fat formation)
  • Does not affect blood glucose or insulin levels
  • Does not elevate IGF-1 or bind the GH receptor
  • May support cartilage repair (emerging research)

Survodutide effects

  • Substantial weight loss (~14-19% at highest doses in phase 2)
  • Suppresses appetite and slows gastric emptying via GLP-1
  • Increases energy expenditure via glucagon receptor activation
  • Reduces liver fat (notable MASH/NASH activity)
  • Improves glycemic control and fasting glucose
  • Lowers LDL cholesterol and triglycerides

AOD-9604 side effects

  • Injection site irritation or redness
  • Occasional headache
  • Mild nausea (uncommon)
  • Transient lightheadedness

Survodutide side effects

  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • Transient heart rate increase (5-10 bpm)
  • Injection site reactions
  • Mild fasting glucose elevation at low doses (resolves with titration)
  • Risk of gallbladder issues with rapid weight loss

AOD-9604 dosing ranges

Fat loss and body composition

250-500 mcg · Once daily (SubQ) · 8-12 weeks

Survodutide dosing ranges

Obesity (phase 2/3 protocol)

0.3-6.0 mg · Once weekly SubQ (titrated) · Long-term (chronic dosing)

MASH / NASH (phase 2)

1.2-6.0 mg · Once weekly SubQ (titrated) · 48 weeks minimum

Type 2 diabetes (phase 2)

0.3-4.8 mg · Once weekly SubQ · Long-term

Full AOD-9604 guide → Full Survodutide guide →

AOD-9604 vs Survodutide — common questions

What is the difference between AOD-9604 and Survodutide?

AOD-9604: Fat-metabolizing fragment of human growth hormone without growth-promoting effects. Typical dose 250-500 mcg. Survodutide: Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials. Typical dose 300-6000 mcg. Both fall under the Weight Management category.

Can you stack AOD-9604 and Survodutide?

Stacking AOD-9604 with Survodutide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, AOD-9604 or Survodutide?

AOD-9604 is typically dosed: Once daily (SubQ) for Fat loss and body composition. Survodutide is typically dosed: Once weekly SubQ (titrated) for Obesity (phase 2/3 protocol); Once weekly SubQ (titrated) for MASH / NASH (phase 2); Once weekly SubQ for Type 2 diabetes (phase 2).

Are AOD-9604 and Survodutide FDA approved?

AOD-9604: Not FDA approved as a drug. Granted GRAS status as a food additive in 2014. Survodutide: Not FDA approved. Investigational compound in phase 3 clinical trials for obesity and MASH/NASH.

Related peptide comparisons

aod-9604 vs cjc-1295aod-9604 vs ftpp-adipotideaod-9604 vs hgh-fragment-176-191aod-9604 vs ipamorelinaod-9604 vs retatrutideaod-9604 vs semaglutide

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free